Enhanced anticancer activity of a combination of docetaxel and Aneustat (OMN54) in a patient‐derived, advanced prostate cancer tissue xenograft model

The current first‐line treatment for advanced metastatic prostate cancer, i.e. docetaxel‐based therapy, is only marginally effective. The aim of the present study was to determine whether such therapy can be improved by combining docetaxel with Aneustat (OMN54), a multivalent botanical drug candidat...

Descripción completa

Detalles Bibliográficos
Autores principales: Qu, Sifeng, Wang, Kendric, Xue, Hui, Wang, Yuwei, Wu, Rebecca, Liu, Chengfei, Gao, Allen C., Gout, Peter W., Collins, Colin C., Wang, Yuzhuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2013
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5528545/
https://www.ncbi.nlm.nih.gov/pubmed/24388358
http://dx.doi.org/10.1016/j.molonc.2013.12.004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5528545/
https://www.ncbi.nlm.nih.gov/pubmed/24388358
http://dx.doi.org/10.1016/j.molonc.2013.12.004

Ejemplares similares